Neoleukin Therapeutics logo
Neoleukin Therapeutics NLTX

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Neoleukin Therapeutics Financial Ratios 2011-2025 | NLTX

Annual Financial Ratios Neoleukin Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

0.1 -0.7 -2.3 -20.5 -4.6 -1.7 -6.1 -9.0 -6.1 -3.8 - - -

P/S

- - - - - 2.1 - - - - - - -

EPS

27.8 -1.0 -1.1 -0.6 -2.6 -1.3 -2.1 -2.0 -1.7 -2.8 -49.5 -40.2 -

EV (Enterprise Value)

-110 M -33.8 M 19.9 M 509 M 180 M -19.3 M 264 M 311 M 98 M 82.3 M -6.12 M 51.4 M -

EBITDA per Share

-106 -0.97 -1.08 -0.879 -0.847 -1.34 -2.14 -1.96 -1.72 -2.57 - - -

EV/EBITDA

0.2 -10.3 -7.6 0.8 -5.0 -8.1 -4.3 -3.5 - - -

PEG

0.0 0.06 0.3 -0.27 0.05 -0.04 0.66 0.68 -0.16 0.05 - - -

P/B

0.0 0.4 1.0 3.6 2.2 0.7 3.1 2.3 1.2 2.5 - - -

P/CF

-0.0 -0.7 -3.0 -25.5 -19.5 -1.7 -6.7 -10.8 -6.5 -5.1 - - -

ROE %

7.34 37.87 -42.48 -17.40 -49.01 -43.46 -50.75 -25.58 -20.16 -66.47 - - -

ROA %

6.13 -50.51 -37.17 -15.81 -47.23 -40.69 -45.48 -23.97 -19.29 -58.00 - - -

ROCE %

-29.88 38.78 -42.49 -20.51 -16.34 -44.70 -51.44 -25.99 -19.66 -61.78 - - -

Current Ratio

6.1 10.3 8.0 24.7 30.3 16.7 9.9 10.9 15.6 7.6 - - -

DSO

- - - - - 3.5 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Neoleukin Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.99 -1.05 -1.08 - -1.19 -1.09 -1 - -32.67 -26.68 -0.26 - -1.18 -0.28 -0.28 - -0.28 -0.27 -0.27 - -0.04 -0.2 -0.18 - -2.26 -0.09 -0.09 - -0.64 0.12 -0.62 - -0.5 -0.59 -0.36 - -0.46 -0.63 -0.39 - -0.43 -0.44 -0.6 - -0.59 -0.51 -1.28 - -15.64 -7.89 -8.48 - - - - - - - -

EBITDA per Share

-1.09 -1.2 -1.2 - -1.26 -1.14 -1.06 - -32.3 -26.5 -0.27 - -1.12 -0.27 -0.27 - -0.26 -0.26 -0.27 - -0.03 -0.19 -0.18 - -2.27 -0.01 - - -0.65 0.11 - - -0.51 -0.6 - - - - - - - - - - - 0.01 0.01 - 0.15 0.05 0.05 - - - - - - - -

ROE %

-38.42 -45.24 -49.12 -36.55 -28.59 -5.92 13.02 -2.49 -14.86 -35.19 -55.65 -37.62 -47.59 -45.19 -40.80 -27.38 -28.56 -19.76 -15.80 -10.79 -52.53 -93.08 -87.99 -43.29 -63.92 -42.82 -38.81 -36.74 -48.70 -40.04 -57.98 -34.30 -39.93 -33.59 -27.21 -17.81 -22.45 -21.46 -18.31 -14.94 -32.32 -45.06 -55.69 -44.09 -38.96 -16.45 -0.21 7.90 7.90 2.77 1.54 - - - - - - - -

ROA %

-34.19 -39.22 -42.10 -22.60 -38.87 -42.83 -45.16 -43.31 -53.64 -47.70 -46.53 -32.07 -40.85 -39.30 -35.94 -24.34 -25.41 -17.70 -14.24 -9.80 -50.02 -89.17 -84.54 -41.72 -61.04 -40.14 -36.38 -34.40 -45.12 -36.53 -52.77 -30.74 -36.02 -30.57 -25.15 -16.68 -21.13 -20.29 -17.42 -14.29 -29.46 -40.19 -49.09 -38.47 -59.99 -66.34 -58.43 -33.16 -33.16 -11.64 -6.46 - - - - - - - -

ROCE %

-43.53 -50.71 -54.15 -40.13 -31.82 -7.37 13.07 -2.85 -15.73 -36.92 -57.97 -38.29 -48.27 -45.36 -40.82 -27.38 -28.56 -19.76 -15.81 -11.03 -53.03 -93.86 -89.06 -42.31 -63.22 -42.13 -38.12 -17.21 -29.42 -20.71 -38.56 -26.36 -26.36 -14.15 - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

12.9 12.4 13.4 13.2 6.2 7.2 - 6.1 6.2 6.5 5.8 5.4 6.0 6.8 7.8 8.0 8.3 9.4 9.5 10.9 10.9 10.9 10.9 27.6 27.6 27.6 27.6 15.7 15.7 15.7 15.7 9.6 9.6 9.6 9.6 15.9 15.9 15.9 15.9 23.0 23.0 23.0 23.0 7.8 7.8 7.8 7.8 2.1 2.1 2.1 2.1 - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Neoleukin Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 1.7 50.0 % $ 183 M canadaCanada
Cronos Group Cronos Group
CRON
$ 3.24 13.51 % $ 1.69 B canadaCanada
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Harrow Health Harrow Health
HROW
$ 47.18 -7.67 % $ 1.54 B usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 5.36 17.8 % $ 86.3 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 11.46 -2.22 % $ 587 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
$ 10.97 0.18 % $ 36.7 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
$ 21.38 -0.05 % $ 2.03 B franceFrance
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.28 2.14 % $ 1.22 B usaUSA
Evolus Evolus
EOLS
$ 6.99 1.09 % $ 433 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 1.67 11.33 % $ 29.2 M chinaChina
Perrigo Company plc Perrigo Company plc
PRGO
$ 13.13 -2.23 % $ 1.8 B usaUSA
ProPhase Labs ProPhase Labs
PRPH
$ 0.12 -15.26 % $ 1.9 M usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 0.93 -2.37 % $ 21.7 M usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.95 -0.93 % $ 2.54 B canadaCanada
SCYNEXIS SCYNEXIS
SCYX
$ 0.64 -0.02 % $ 30.6 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
$ 0.77 -1.79 % $ 54.7 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.88 14.72 % $ 402 M canadaCanada
Solid Biosciences Solid Biosciences
SLDB
$ 5.85 -0.34 % $ 239 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 4.83 1.15 % $ 636 M usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 3.59 -3.37 % $ 4.46 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 2.61 4.99 % $ 36.7 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.12 -1.67 % $ 124 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Sundial Growers Sundial Growers
SNDL
$ 2.19 24.01 % $ 3.37 M canadaCanada
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Veru Veru
VERU
$ 2.45 -4.3 % $ 330 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
cbdMD cbdMD
YCBD
$ 1.18 87.31 % $ 5.09 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Tilray Tilray
TLRY
$ 11.86 40.68 % $ 7.33 B canadaCanada
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.79 -2.72 % $ 18.7 M usaUSA